Ovarian Neoplasms: all 2,757 studies

Page 10 of 28. Open to participants first (735), then studies with results posted, then the rest; newest registration first within each.

• TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian CancerCompletedNCT02764333Phase 2Results posted
• Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerCompletedNCT02759588Phase 1/2Results posted
• Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus NormothermiaCompletedNCT02739698Phase 2Results posted
• A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.Active, not recruitingNCT02734004Phase 1/2Results posted
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)TerminatedNCT02718417Phase 3Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.TerminatedNCT02711345Phase 1Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)CompletedNCT02674061Phase 2Results posted
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsTerminatedNCT02669914Phase 2Results posted
• Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
• A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT02655016Phase 3Results posted
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1Active, not recruitingNCT02650986Phase 1/2Results posted
• FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian CancerTerminatedNCT02641639Phase 2/3Results posted
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerCompletedNCT02631876Phase 3Results posted
• Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02627443Phase 1Results posted
• A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian CancerCompletedNCT02608684Phase 2Results posted
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
• EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial SarcomaCompletedNCT02601937Phase 1Results posted
• Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02595892Phase 2Results posted
• A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)CompletedNCT02580058Phase 3Results posted
• Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal CancerTerminatedNCT02575807Phase 1/2Results posted
• Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerTerminatedNCT02569957Phase 2Results posted
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
• Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian CancerTerminatedNCT02540356Phase 1/2Results posted
• Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)CompletedNCT02537444Phase 2Results posted
• Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingNCT02502266Phase 2/3Results posted
• Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell TumorsTerminatedNCT02499952Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02498600Phase 2Results posted
• Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersCompletedNCT02487095Phase 1/2Results posted
• To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerCompletedNCT02476968Phase 4Results posted
• Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02470585Phase 3Results posted
• Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian CarcinomaTerminatedNCT02469116Phase 2Results posted
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02446600Phase 3Results posted
• Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian CancerCompletedNCT02440425Phase 2Results posted
• A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 ElevationTerminatedNCT02432690Phase 2Results posted
• Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerCompletedNCT02431559Phase 1/2Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer PatientsCompletedNCT02421588Phase 3Results posted
• AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant AscitesTerminatedNCT02417753Phase 2Results posted
• Fermented Wheat Germ Extract in Women With Ovarian CancerTerminatedNCT02411565Early Phase 1Results posted
• A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedNCT02389985Phase 1/2Results posted
• MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerTerminatedNCT02364713Phase 2Results posted
• A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensCompletedNCT02354586Phase 2Results posted
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results posted
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)CompletedNCT02327078Phase 1/2Results posted
• BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor TreatmentTerminatedNCT02326844Phase 2Results posted
• Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4CompletedNCT02326064Results posted
• Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian CancerCompletedNCT02317705Phase 2Results posted
• Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02312245Phase 2Results posted
• Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal CancerCompletedNCT02311907Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian CancerCompletedNCT02289950Phase 2Results posted
• Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02283658Phase 2Results posted
• Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum TreatmentsCompletedNCT02282020Phase 3Results posted
• Ovarian Cancer Patient-Centered Decision AidCompletedNCT02259699Not applicableResults posted
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02203513Phase 2Results posted
• Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02159989Phase 1Results posted
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingNCT02142803Phase 1Results posted
• Photoacoustic Imaging of the OvaryTerminatedNCT02110277Not applicableResults posted
• Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02101775Phase 2Results posted
• p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246CompletedNCT02098343Phase 1/2Results posted
• MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT02068794Phase 1/2Results posted
• Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-TreatmentTerminatedNCT02035345Phase 4Results posted
• Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic MalignanciesCompletedNCT02025985Phase 2Results posted
• GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian CancerTerminatedNCT02012192Phase 1/2Results posted
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
• A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian CancerCompletedNCT02004093Phase 2Results posted
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02001623Phase 1/2Results posted
• Tivozanib As Maintenance Therapy In GYNTerminatedNCT01972516Phase 2Results posted
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedNCT01968213Phase 3Results posted
• Trial of Pimasertib With SAR245409 or Placebo in Ovarian CancerCompletedNCT01936363Phase 2Results posted
• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsTerminatedNCT01905592Phase 3Results posted
• A Study Of PF-06263507 In Patients With Advanced Solid TumorsTerminatedNCT01891669Phase 1Results posted
• A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)CompletedNCT01891344Phase 2Results posted
• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyActive, not recruitingNCT01874353Phase 3Results posted
• Salvage Ovarian FANG™ Vaccine + CarboplatinumCompletedNCT01867086Phase 2Results posted
• A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerTerminatedNCT01849874Phase 3Results posted
• A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerCompletedNCT01847274Phase 3Results posted
• A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01846611Phase 3Results posted
• Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.Active, not recruitingNCT01844986Phase 3Results posted
• A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based ChemotherapyTerminatedNCT01840943Phase 3Results posted
• Palifosfamide in Treating Patients With Recurrent Germ Cell TumorsTerminatedNCT01808534Phase 2Results posted
• A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian CancerTerminatedNCT01773889Phase 2Results posted
• MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentCompletedNCT01770353Phase 1Results posted
• Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT01767675Phase 2Results posted
• A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric CancersCompletedNCT01743469Phase 2Results posted
• Sentinel Node Detection in Clinical Early Stage Ovarian CancerCompletedNCT01734746Not applicableResults posted
• Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)Active, not recruitingNCT01696994Not applicableResults posted
• SGI-110 in Combination With Carboplatin in Ovarian CancerCompletedNCT01696032Phase 2Results posted
• Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)CompletedNCT01684878Phase 3Results posted
• Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal CancerTerminatedNCT01681368Phase 2Results posted
• BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian CancerCompletedNCT01669798Phase 2Results posted
• VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT01666444Phase 2Results posted
• A Study LY2228820 for Recurrent Ovarian CancerCompletedNCT01663857Phase 1/2Results posted
• A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube CancersTerminatedNCT01659554Phase 2Results posted
• Dose-finding Study in Platinum-Resistant Ovarian CancerCompletedNCT01653912Phase 1/2Results posted
• Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 StudyCompletedNCT01617629Phase 2Results posted
• Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian CancerCompletedNCT01611558Phase 2Results posted
• A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian CancerCompletedNCT01610206Phase 2Results posted
• CT Antigen TCR-redirected T Cells for Ovarian Cancer.CompletedNCT01567891Phase 1/2Results posted
• Salvage Ovarian FANG™ Vaccine + BevacizumabCompletedNCT01551745Phase 2Results posted

← Ovarian Neoplasms overview